More reads
- Taking stock of Alzheimer’s research: Experts offer takes on Biogen, the NIH, and the amyloid hypothesis. (STAT Plus)
- Pfizer smashes expectations with tafamidis launch. (EP Vantage)
- Amgen third-quarter revenue falls 3%, biosimilar sales rise. (Reuters)
- The ‘cancer growing in cancer medicine’: pharma money paid to doctors. (STAT)
No hay comentarios:
Publicar un comentario